Published in J Neurol Sci on September 03, 2011
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology (2013) 2.99
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. Am J Hum Genet (2008) 2.58
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord (2010) 2.34
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2011) 2.12
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet (2008) 1.95
Epilepsy and mental retardation limited to females: an under-recognized disorder. Brain (2008) 1.94
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 1.94
Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol (2011) 1.91
PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet (2012) 1.91
Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord (2009) 1.90
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep (2012) 1.68
Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Mol Genet (2003) 1.65
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol (2010) 1.57
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord (2009) 1.54
Reliability of brain CT evaluation by stroke neurologists in telemedicine. Neurology (2012) 1.54
Rapidly progressive diffuse Lewy body disease. Mov Disord (2011) 1.52
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord (2006) 1.49
Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. Sleep (2008) 1.49
Autonomic function and cerebral autoregulation in patients undergoing carotid endarterectomy. Circ J (2010) 1.45
Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg (2011) 1.42
Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain (2008) 1.41
Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord (2007) 1.41
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol (2010) 1.41
Cognitive dysfunction and dementia in Parkinson disease. Mov Disord (2007) 1.39
Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep (2012) 1.36
Clinical overview of the synucleinopathies. Mov Disord (2003) 1.36
Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord (2007) 1.35
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol (2010) 1.34
Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 1.34
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Mitochondrial cytopathies. J Neurol (2003) 1.28
Computer-based, personalized cognitive training versus classical computer games: a randomized double-blind prospective trial of cognitive stimulation. Neuroepidemiology (2011) 1.26
Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord (2007) 1.26
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry (2007) 1.24
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol (2006) 1.23
Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp (2011) 1.23
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord (2014) 1.23
The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord (2014) 1.21
Genes associated with Parkinson syndrome. J Neurol (2008) 1.21
The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. Stem Cells (2007) 1.21
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol (2005) 1.18
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease. Eur J Neurosci (2009) 1.14
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord (2006) 1.13
Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord (2004) 1.12
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol (2009) 1.12
Health-related quality of life in multiple system atrophy. Mov Disord (2006) 1.11
A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson's disease. Ann Neurol (2004) 1.11
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord (2007) 1.11
White matter changes in multiple sclerosis: correlation of q-space diffusion MRI and 1H MRS. Magn Reson Imaging (2005) 1.09
Neuroanatomical substrate of visuospatial and visuoperceptual impairment in Parkinson's disease. Mov Disord (2009) 1.09
Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord (2004) 1.09
Transient arrest of psychogenic tremor induced by contralateral ballistic movements. Neurosci Lett (2004) 1.08
Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transm (Vienna) (2010) 1.08
Cortical thinning is associated with disease stages and dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry (2013) 1.07
Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol (2005) 1.07
Premotor signs and symptoms of multiple system atrophy. Lancet Neurol (2012) 1.06
Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations. Ann Neurol (2004) 1.06
Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol (2008) 1.05
Different odor tests contribute differently to the evaluation of olfactory loss. Chem Senses (2007) 1.05
Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease. J Neurol Sci (2011) 1.05
Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord (2002) 1.04
Functional brain networks and cognitive deficits in Parkinson's disease. Hum Brain Mapp (2014) 1.03
Usefulness of the SINBAR electromyographic montage to detect the motor and vocal manifestations occurring in REM sleep behavior disorder. Sleep Med (2011) 1.03
Autonomic function in mice lacking alpha5 neuronal nicotinic acetylcholine receptor subunit. J Physiol (2002) 1.03
Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry (2009) 1.02
Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord (2014) 1.02
Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord (2009) 1.02
Depression and Parkinson's disease. J Neurol (2004) 1.02
Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci (2006) 1.02
MRI and cognitive impairment in Parkinson's disease. Mov Disord (2009) 1.02
Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol (2012) 1.01
Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord (2005) 1.01
Utility of the WHO-Five Well-being Index as a screening tool for depression in Parkinson's disease. Mov Disord (2010) 1.00
Autonomic impairment in amyotrophic lateral sclerosis. Curr Opin Neurol (2005) 1.00
Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci (2009) 1.00
A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease. J Neurol (2008) 1.00